MAPT and Alzheimer disease: However, for p-tau and Aβ42/p-tau, studies including follow-up periods >24 months coincided with studies with AD diagnosis at follow-up; and for p-tau and Aβ42/T-tau, studies using xMAP technology coincided with studies including MCI cases older than 70 years (and vice versa only for Aβ42/T-tau: ELISA technology with studies including MCI cases younger than 70 years).